跳转至内容
Merck
CN

M2727

美西律 盐酸盐

≥98% (GC), powder, sodium channel blocker

别名:

1-(2,6-二甲基苯氧基)-2-丙胺 盐酸盐, 1-(2,6-二甲基苯氧基)-2-丙胺盐酸盐 盐酸盐

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式(希尔记法):
C11H17NO · HCl
化学文摘社编号:
分子量:
215.72
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
250-825-7
MDL number:
Assay:
≥98% (GC)
Form:
powder
Quality level:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


产品名称

美西律 盐酸盐, powder

assay

≥98% (GC)

Quality Level

form

powder

color

white to off-white

solubility

methanol: 50 mg/mL

originator

Boehringer Ingelheim

storage temp.

2-8°C

SMILES string

Cl[H].CC(N)COc1c(C)cccc1C

InChI

1S/C11H17NO.ClH/c1-8-5-4-6-9(2)11(8)13-7-10(3)12;/h4-6,10H,7,12H2,1-3H3;1H

InChI key

NFEIBWMZVIVJLQ-UHFFFAOYSA-N

General description

美西律是一种IB类抗心律失常药,是利多卡因的类似物。它的半衰期为10-12小时,在肝脏中代谢,通过还原、氧化或结合反应消除。

Application

盐酸美西律可作为钠离子通道阻滞剂用于:
  • 中国仓鼠卵细胞
  • 人胚胎肾 (HEK) 细胞,用于全细胞膜片钳研究
  • 表达Nav1.7蛋白的HEK细胞的电生理研究

Biochem/physiol Actions

美西律是一种有效的钠离子通道阻滞药。它是一种抗心律失常药,在头疼和神经性疼痛中可作为辅助药物美西律用于治疗钠离子通道病的肌强直症状,并缩短心脏动作电位的去极化时程,但不会对心房不应期造成影响。它对钠通道的抑制作用可有效治疗钾加重性肌强直。

Features and Benefits

该化合物由 Boehringer Ingelheim 开发。想要浏览其他由制药公司开发的化合物以及已批准药物/候选药物清单,请单击此处


Still not finding the right product?

Explore all of our products under 美西律 盐酸盐


pictograms

Exclamation mark

signalword

Warning

hcodes

Hazard Classifications

Acute Tox. 4 Oral

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库



K Mori et al.
Naunyn-Schmiedeberg's archives of pharmacology, 358(6), 641-648 (1999-01-08)
Recently we have reported that class III antiarrhythmic drugs including amiodarone inhibit the Na+-activated K+ (KNa) channels in isolated cardiac cells. In this study effects of antiarrhythmic drugs having class I and/or IV properties on the single KNa channel current
S Sicouri et al.
Journal of cardiovascular electrophysiology, 8(11), 1280-1290 (1997-12-12)
Recent clinical studies have reported a greater effectiveness of sodium channel block with mexiletine to abbreviate the QT interval in patients with the chromosome 3 variant (SCN5A, LQT3) of the long QT syndrome (LQTS) than those with the chromosome 7
E L Logigian et al.
Neurology, 74(18), 1441-1448 (2010-05-05)
To determine if mexiletine is safe and effective in reducing myotonia in myotonic dystrophy type 1 (DM1). Myotonia is an early, prominent symptom in DM1 and contributes to decreased dexterity, gait instability, difficulty with speech/swallowing, and muscle pain. A few



全球贸易项目编号

货号GTIN
M2727-100G04061832574851
M2727-25G04061834045960